EAP for convalescent plasma no longer enrolling; the FDA authorized emergency use.

See "EAP to EUA transition" box for physician instructions

Learn more

Program Highlights

  • New England Journal of Medicine publishes paper

    A paper, “Convalescent Plasma Antibody Levels and the Risk of Death from COVID-19,” describes the association Mayo Clinic researchers and collaborators found between administration of convalescent plasma containing high antibodies and lower mortality rates for hospitalized patients with COVID-19 who are not on ventilators. Read more.

  • Uscovidplasma.org included in national archive

    The Library of Congress has selected the USCOVIDplasma.org website for inclusion in the nation's historic Coronavirus Web Archive. Mayo Clinic developed the website to facilitate the nation's Expanded Access Program (EAP) for convalescent plasma to treat COVID-19. Selection for the archive demonstrates the significant role of the EAP in the US response to the pandemic, and Mayo Clinic's leadership role. Access to the site will be available at the Library of Congress in Washington, D.C., and on the library's public access website as early as fall 2021.

  • Data analysis

    The EAP team continues to analyze data from the program and publish its findings, which were an important component of the scientific evidence considered by the U.S. Food and Drug Administration in the decision to issue an Emergency Use Authorization on August 23, 2020, to permit the use of convalescent plasma for treatment in hospitalized patients with COVID-19.

Historical EAP program participation

Participating locations and enrolled providers

  • Sites
  • Physicians
  • Patients
  • Infused